Natural history study of Usher syndrome hearing and vision changes
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This study follows people with Usher syndrome over time to better understand how hearing and vision symptoms change. It may help researchers measure disease progression and support future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Usher syndrome type 1, 2, or 3 (either diagnosed clinically or confirmed by genetic testing).
- If your diagnosis is not yet genetic, the study will confirm it with molecular (genetic) testing.
- You have health insurance (or are covered as a study beneficiary).
- You (or your legal representative) can sign an informed consent form and agree to take part.
- You must be able to understand the study, and consent must be possible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
This study follows children with hearing loss caused by changes in specific genes (GJB2 or OTOF). It helps researchers understand how hearing develops over time and how children may do with or without cochlear implants.
This trial tests a drug called NPI-001 (N-acetylcysteine) to see if it can help protect the light-sensing cells in the eyes of people with Usher syndrome, a genetic condition that causes vision and hearing loss. The study lasts 24 months and measures how well the retina stays healthy.
This study follows people and families with autosomal dominant inherited hearing loss to better understand how it progresses. It may help researchers learn what to expect over time and guide future treatment planning.
This trial tests an experimental gene therapy given as an injection under the retina. It aims to slow or stop vision loss in people with Usher syndrome type 1B, a rare genetic condition that causes both hearing and vision problems.
This trial tests an oral medication (NPI-001) to see if it can preserve the light-sensing cells in the retina for people with retinitis pigmentosa caused by Usher syndrome. It lasts 24 months and requires several eye exams to monitor changes.
Hear when a new Usher Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.